Medical device major Medtronic, Inc. (MDT) has initiated the global launch of its latest blood glucose sensor – the MiniMed 640G System. Apart from monitoring a patient's blood glucose level, the system also manages the level by delivering insulin as per the individual's need.
Notably, this is the world's first insulin therapy system that can automatically stop delivering insulin before the glucose level has reached a low range pre-set in the sensor, thereby preventing the occurrence of hypoglycemia. Additionally, this system can resume insulin delivery once the glucose levels are recovered, thereby preventing hyperglycemic rebounds.
In a way, Medtronic's MiniMed 640G System acts like an artificial pancreas by managing hypoglycemia and rebound hyperglycemia. Incidentally, these are the biggest challenges that physicians face when attending diabetic patients.
Currently, this insulin therapy system is available in Australia, while launch in other markets awaits local approvals. The wait is expected to be over in the next few months.
The MiniMed 640G System incorporates the SmartGuard technology, Enhanced Enlite sensor and the Bayer CONTOUR NEXT LINK 2.4 blood glucose meter.
Management believes that the launch of the MiniMed 640G System marks the third significant milestone in Medtronic's efforts that are targeted toward creating the world`s first artificial pancreas.
In its last reported second-quarter fiscal 2015 results, Medtronic delivered 8.6% growth in its diabetes segment, on the back of strong performance of Medtronic's MiniMed 530G with Enlite CGM sensor in the U.S. We believe the launch of MiniMed 640G, an advanced version of MiniMed 530G, will fetch more profits for the company in the coming quarters.
Currently, Medtronic has a Zacks Rank #3 (Hold). Some better-ranked medical products stocks include ICU Medical, Inc. (ICUI), Cardiovascular Systems Inc. (CSII) and Conatus Pharmaceuticals Inc. (CNAT). While ICU Medical sports a Zacks Rank #1 (Strong Buy), Cardiovascular Systems and Conatus Pharmaceuticals hold a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment